Tumor necrosis factor receptor superfamily member 17 ( TNFRSF 17) , also known as B cell maturation antigen ( BCMA ) or CD 269 antigen, is one of the members of the tumor necrosis factor receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes and is involved in B cell development and autoimmune response. This receptor has been shown to specifically bind to tumor necrosis factor (ligand) superfamily member 13B (TNFSF13BABAFF) , and cause NF- kappa B and MAPK8/JNK activation. BCMA also binds to different members of the TRAF family to mediate the transmission of cell survival and proliferation signals, so it can be used as a molecular target for drug development for certain immunodeficiency or autoimmune diseases. In BCMA as a target CAR-T has been in clinical trials for multiple myeloma. This product is a BCMA-FC recombinant protein (FC tag can be removed by enterokinase), which can be used for monoclonal antibody screening or antibody function verification.

Product name: Recombinant human BCMA protein

Species: Human origin

Gene sequence number: NP_001183.2

Tags: Human-Fc Tag

Tag site: N- terminal

Restriction site: enterokinase

Expression area: extracellular segment ( 1-54AA )

Host cell: 293F

Purity:> 90%

Purification method: Protein A column

Preservation system: PBS+20% glycerol

Storage conditions: -80℃

Illustration: Lane M on the left is protein MW marker, Lane 1 is 10ug BCMA-Fc protein;

The image on the right shows the FACS detection of the binding of BCMA protein to 293T overexpressing anti-BCMA-CAR.